Exelixis Announces Appellate Court Affirms Key Part Of 2024 Judgement Of U.S. District Court In Favor Of Co. Against MSN Laboratories; Appellate Court Upholds District Court Decision That Three Patents Are Not Invalid Covering Crystalline Malate Salt Of Cabozantinib
Exelixis, Inc. (NASDAQ:EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN Laboratories Private Limited et al. (MSN), Civil Action No. 22-00228 (Consolidated), the U.S. Court of Appeals for the
A higher court agreed that Exelixis's three important medicine patents are real and valid, protecting their cancer drug from copycat makers. This is good news because it means the company can keep selling their drug without competition from cheaper copies for longer.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.